Mycotopia Therapies looking to unlock the full potential of psychedelic-derived medicines; Create Active Pharmaceutical Ingredient (API) for magic mushroom
MIAMI, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia...
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform
News Channel 5 Nashville. Ketamine infusions are being used to treat patients with severe depression. The medicine is also a treatment for curb substance abuse addictions.
Pasithea Therapeutics recently raised $24 million at its initial public offering (“IPO”). The Company’s Common Stock began trading on The Nasdaq Capital Market on September 15, 2021, under the...
"I believe that we are on the verge of curing, as opposed to simply treating, certain psychiatric maladies." Dr. Jeffrey Kamlet, Chief Medical Officer of Ehave.
Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base
Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-yearExceeding monthly...
Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development, Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage
National Presence Will Bring...
Psycheceutical's Safer Psychedelic Medicines, for Better Mental Health Treatments.
Our Favorite Psychedelic Company With a Non-Hallucinogenic Delivery Mechanism, That...
